World Health Organization Finalizes Distinct Naming Scheme for Biological Medicines

After years of international debate, the World Health Organization has issued its final proposal embracing distinct names for biological medicines, including biosimilars. The organization opts for four-letter biological qualifiers to follow biological medicines’ international nonproprietary name.   The approach acknowledges patient and advocates’ concerns that distinct names be applied to ensure clarity, patient safety and the ability to track adverse events to their source….

Read more at the Institute for Patient Access